Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by STOCKMAN70on Sep 10, 2016 6:26pm
250 Views
Post# 25225531

RE:RE:RE:3D Signatures Partnership with Knight

RE:RE:RE:3D Signatures Partnership with KnightI bought into the 3D deal through Haywood. The value to the drug companies is huge in my opinion, it has the potential to save them millions in costs and reduce the time from trial to market by years. obvuously they would be willing to,pay a handsome price for this technology. On the prognostic side 3d's technology enables doctors to know what the best course of action is based on each patients specific situation, which can save insurance companies millions In drug costs as some patients will respond well to less expensive treatments. And for patients it could be he difference between life and death; if your doctor doesn't know how you will respond to different treatment options they may not get you the treatment you need before it's too late, but using 3d's technology and simply taking a blood test you can find out the treatment that is best for your situation in a very short period of time. LDT approval expected within 6 months followed closely by CLIA approval in the US. With the Knight and Goodman stamp of approval and advisory services definitely worth taking a look into for a long term investment. Starts trading this Tuesday under DXD.v.
Bullboard Posts